冠昊生物收盘下跌1.25%，滚动市盈率157.24倍，总市值43.86亿元

Group 1 - The core business of the company focuses on developing new products and technologies with independent intellectual property rights, aiming to enhance product quality and optimize product structure [2] - The main products include biological dura (spinal) membrane patches, B-type dura (spinal) membrane patches, thoracic repair membranes, sterile biological dressings, and other specialized medical materials [2] - The company has achieved a revenue of 94.8 million yuan in Q1 2025, representing a year-on-year growth of 3.67%, with a net profit of 14.9 million yuan, also up by 3.30%, and a gross profit margin of 77.05% [2] Group 2 - As of June 5, the company's stock closed at 16.54 yuan, down 1.25%, with a rolling PE ratio of 157.24 times, and a total market capitalization of 4.386 billion yuan [1] - The average PE ratio in the medical device industry is 50.97 times, with a median of 36.67 times, placing the company at the 112th position in the industry ranking [1][3] - On June 5, the net outflow of main funds for the company was 19.1 million yuan, although there was an overall inflow of 32.2 million yuan over the past five days [1]